Wall Street’s Recommendations for BSX Stock



Analysts’ recommendations for Boston Scientific

Boston Scientific (BSX) has added a number of products to its portfolio through various strategic acquisitions, the latest being that of Securus Medical, discussed in the previous article of this series. Other recent acquisitions include that of NxThera and EMcision. In this article, we’ll discuss analysts’ recent recommendations and target prices for BSX stock.

As of April 4, 2018, of the 25 analysts covering Boston Scientific, 20 (80%) have recommended “buy” or “strong buy,” while five (20%) have recommended “hold.” There have been no “sell” recommendations.
Article continues below advertisement

Target price

As of April 4, 2018, analysts’ 12-month price target for BSX stock was $31.63, implying a return of ~15.2% based on the stock’s closing price of $27.46 on April 3, 2018.

On April 4, peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had 12-month price targets of $68.33, $145, and $91.15, respectively, representing potential returns of 15.8%, 6.1%, and 16.3% over the next 12 months.

Wall Street recommendations and updates

On March 27, 2018, Needham reiterated its “buy” rating on BSX stock. It has a price target of $35 on the stock. On March 19, 2018, Morgan Stanley raised its 12-month price target on BSX stock from $30 to $33. In February 2018, Piper Jaffray initiated coverage on Boston Scientific with an “overweight” rating.


More From Market Realist